BioNTech SE
BioNTech SE (FWB: 22UA) is trading at €85.70, about ₹9,334 at today's EUR/INR rate, as of 30 Sep 2026, 9:31 AM ET, down 0.75% today. Indian residents can buy BioNTech from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
€85.55
Today's high
€86.65
52 week low
€68.00
52 week high
€105.70
22UA opened at €86.20, closed previously at €86.35, and has traded between €68.00 and €105.70 over the past 52 weeks.
About
BioNTech SE is a biotechnology firm dedicated to the research, development, and marketing of immunotherapies for oncology and a spectrum of infectious diseases. Its diverse product pipeline features several FixVac candidates, including BNT111, currently undergoing Phase II clinical trials for advanced melanoma; BNT112, in Phase I/IIa development for prostate cancer; BNT113, progressing through Phase II for HPV-positive head and neck cancers; BNT114, in Phase I for triple-negative breast cancer; BNT115, also in Phase I for ovarian cancer; and BNT116, a preclinical asset targeting non-small cell lung cancer. Further expanding its oncology focus, BioNTech is advancing neoantigen-specific immunotherapies like Autogene cevumeran (BNT122), which is in Phase II trials for first-line melanoma and Phase 1a/1b trials for multiple solid tumors. The company's mRNA intratumoral immunotherapy, SAR441000, is undergoing Phase I evaluation for solid tumors, complemented by additional neoantigen-specific programs BNT141 and BNT142, both in Phase I clinical studies for various solid malignancies. The firm's portfolio also encompasses RiboCytokines, such as BNT151, BNT152, and BNT153, designed to treat solid tumors. Chimeric antigen receptor T cell (CAR T) immunotherapies include BNT211, aimed at multiple solid tumors, and BNT221 for other cancer types. Additionally, checkpoint immunomodulators GEN1046 and GEN1042 are in Phase I/II clinical development for solid tumor indications. Beyond these, BioNTech is developing BNT321, an IgG1 monoclonal antibody in Phase II trials for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. The company is also actively involved in the creation of prophylactic vaccines for COVID-19 and Influenza, alongside other infectious disease immunotherapies and therapies for rare diseases involving protein replacement. BioNTech maintains strategic alliances with several prominent pharmaceutical and biotechnology entities, including Genentech, Inc., Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE's corporate headquarters are located in Mainz, Germany.
Key statistics
Avg. volume
50.99K
Market cap
€21.53B
P/E Ratio
-12.70
Price-to-sales ratio
8.14
Enterprise value
€12.25B
Free cash flow yield
1.37%
Debt-to-equity ratio
0.02
Return on equity
-5.68%
ROIC
-3.14%
Beta
1.28
Dividend yield
0.00%
Last dividend
€0.00
Financial overview
Revenue
€2.76B
Earnings per share
-€4.52
Free cash flow
€269.91M
Net profit margin
-64.25%
Gross margin
68.95%
EBITDA
-€256.27M
Revenue growth
0.24%
Similar securities
This is not an investment recommendation
How to buy BioNTech from India
Indian residents can buy BioNTech shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to EUR.
Search for BioNTech and place an order
Find BioNTech by name or by its ticker, 22UA, and choose an order type. BioNTech trades 11:30 am – 11:30 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your BioNTech position in EUR and INR. BioNTech pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in BioNTech from India
Trading and taxes when buying BioNTech from India
Trading and limits
- Trading hours
- 8:00 am – 8:00 pm CET
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneBioNTech does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy BioNTech stock?
Yes. BioNTech (22UA) has been listed on the Frankfurt Stock Exchange since 2019, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to EUR. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one BioNTech share cost in rupees?
One BioNTech share is €85.70 — about ₹9,334 at an EUR/INR rate of 108.91 on 29 Sep 2026. Both the BioNTech price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying BioNTech from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
How are gains on BioNTech shares taxed in India?
Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the EUR/INR rate on the purchase and the sale date, so the rupee move counts alongside the BioNTech price. Paasa issues a capital-gains statement for your return.
Does BioNTech pay a dividend?
No. BioNTech does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade BioNTech from India?
The Frankfurt Stock Exchange trades 11:30 am – 11:30 pm IST in Indian time. The window shifts to 12:30 pm – 12:30 am IST when Germany is on standard time. Orders can only execute during that window.
Do I have to declare BioNTech shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your BioNTech holding, its cost and its closing value.
How do I sell BioNTech and bring the money back to India?
You sell during market hours (11:30 am – 11:30 pm IST) and the proceeds settle in EUR in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.
Does the rupee rate affect what I make on BioNTech?
Yes. BioNTech is priced in EUR, so your rupee outcome combines the EUR move with the EUR/INR move between the day you remit and the day you convert back. Both directions are reflected in the capital-gains statement Paasa issues.